Extracorporeal photochemotherapy (ECP) is widely used to treat cutaneous T cell lymphoma, graft versus host disease and allografted organ rejection. Its clinical and experimental efficacy in both cancer immunotherapy and autoreactive disorders suggests a novel mechanism. This study reveals that ECP induces a high percentage of processed monocytes to enter the dendritic antigen presenting cell (DC) differentiation pathway, 
Introduction
Extracorporeal Photochemotherapy (ECP) was originally designed as blooddirected palliative chemotherapy for lymphocytic leukemias, in which the natural plant product 8-methoxypsoralen (8-MOP) is ultraviolet-activated to a transient state which covalently crosslinks thymine bases of DNA.
1 Surprisingly, the original Phase I/II clinical trial, in which less than 5 percent of the body's circulating malignant T cells were extracorporeally exposed to activated 8-MOP, stimulated clinically significant persistent immunologic responses to the reinfused damaged malignant T cells. 2 Since that serendipitous finding, the world-wide accelerating use of ECP has generated clinical responses in cancer (cutaneous T cell lymphoma, CTCL), organ transplant recipients, and acute and chronic graft-versus host disease (GVHD). 3, 4 These high clinical success rates, in otherwise therapeutically resistant situations, coupled with low toxicity and no recognized autoimmune sequelae, 5 have led clinicians in tertiary care centers throughout the United States and Europe to administer ECP cell therapy one and a half million times. However, the fundamental principles underlying these clinical responses, involving immunostimulation in CTCL and immunosuppression and regulation in GVHD, have remained elusive, despite extensive scientific investigation in specifically designed experimental systems. 4, 6 A recent potentially elucidating insight into ECP's mechanism was the finding that the extracorporeal routing of patient blood through the 1mm space between the ultraviolet exposure plates caused large scale conversion of passaged blood monocytes, from treated CTCL subjects, into leukocytes with features typical of dendritic antigen Normal subjects: To determine whether ECP induces monocytes from healthy subjects to convert to DC, mononuclear leukocytes from normal subjects were examined in two ways. Leukapheresed leukocytes from normal subjects (N=3) were studied pretreatment (Pre ECP), immediately after ECP (ECP Day 0) and 18hr post ECP (ECP Day 1). A desktop apparatus, incorporating a UVA light source and a plastic exposure plate, enabled laboratory reproduction of the clinical ECP system and sample access for parallel RNA isolation, immunophenotyping, and functional studies. Alternatively, a unit of blood from normal subjects was drawn into a transfer bag and passed through the ECP treatment apparatus in an identical fashion to that of treated patients (N=3). The cells obtained from the unit of normal blood were used for microarrays, and antigen presentation assays.
Psoralen addition:
As is routinely done during ECP, the standard 8-MOP concentrated solution (Therakos) was added directly to the clinical ECP apparatus and to the For personal use only. on January 15, 2018. by guest www.bloodjournal.org From laboratory model system. That mode of introduction enabled precise 100-200 ng/ml concentrations throughout the clinical procedures and experimentation.
Overnight culture: In ECP, it is not possible to examine phenotypic and functional changes in treated monocytes, since those cells are immediately reinfused into patients. Therefore, after ECP, cells were cultured for 18 hours (RPMI 1640/15% autologous serum) to study induced monocyte gene activation, maturation and function. Prior to ("pre ECP"), and immediately after ECP ("ECP Day 0"), patient and normal subject samples were isolated by centrifugation over a Ficoll-Hypaque gradient. The cells were resuspended in RPMI-1640 medium (Gibco), supplemented with 7.5% AB serum, 7.5% autologous serum (Gemini Bio-Products) and cultured (for patients) in 6-well polystyrene tissue culture plates at a density of 5 x 10 6 cells/ml and in Baxter platelet storage bags (for normal subjects 37°C, 5% CO 2 ). Following overnight culture ("ECP (Figure 7 , discussed more fully in the Results Section) that multiple step magnetic bead removal of apoptotic lymphocytes, performed as follows and yielding monocyte purity of greater than 95%, does not alter levels of observed gene expression in the studied cell populations. To accomplish that comparison we modified the monocyte purification procedure by adapting a negative selection protocol using magnetic beads and the EasySep magnet.
PBMC were centrifuged at low speed (120 x g, 10 min) to remove platelets. Cells were then labeled using the Monocyte Isolation Kit II (Miltenyi Biotec) following the manufacturers procedure with the following modifications: 1) buffer consisted of ice cold PBS containing 2% autologous serum and 1 mM EDTA; 2) blocking time was increased to 10 min; 3) labeling with the Biotin-Antibody Cocktail was increased to 20 min; and 4)
For personal use only. on January 15, 2018. by guest www.bloodjournal.org From cells were washed once between labeling with the Biotin-Antibody Cocktail and the AntiBiotin Microbeads. In order to avoid stimulating the monocytes by passing them over a column, the magnetically labeled cells were instead separated from the unlabeled monocytes using the EasySep magnet (Stem Cell Technologies). Cells, in 2 ml buffer in a 5 ml polystyrene tube, were placed in the magnet for 10 minutes, then the unlabeled cells were carefully poured off into a new tube. This procedure was repeated two times, to maximally enhance monocyte purity. At this point, because the purity was still insufficient, cells were re-labeled with the Monocyte Isolation Kit II reagents, placed in the EasySep magnet for an additional 10 minutes, and the unlabeled monocytes eluted.
Final purity (X=96%+4.5) was assessed by flow cytometric analysis of CD14 staining. and CD80 and CD86 (B7.1 and B7.2 co-stimulatory molecules). [11] [12] [13] Antibodies were obtained from Beckman Coulter and used at their pre-determined optimal dilutions.
Background staining was established with appropriate isotype controls, and immunofluorescence was analyzed using a FC500 flow cytometer (Beckman Coulter).
Combined membrane and cytoplasmic staining was performed following manufacturer's instructions for cell fixation and permeabilization (Intraprep kit, Beckman Coulter).
Antigen presentation assay: Volunteer freshly isolated, magnetic bead-enriched, antigen-experienced CD4 + populations (2 x 10 6 /cc, 50 μl/well) were added to monocytes (2 x 10 6 /cc, 50 μl/well) in the presence of tetanus toxoid (10 μg/ml, 100 μl/well) and RPMI 1640/15% autologous serum. After 5 days of culture, the cells received 1 μCi For personal use only. on January 15, 2018. by guest www.bloodjournal.org From
Results

Phenotypic evidence for a monocyte to DC transition
We first determined whether our previous preliminary finding, that ECP induces a dendritic cell phenotype on ECP-processed monocytes from CTCL patients, 7 is a general phenomenon or merely limited to the CTCL clinical setting. We assessed co-expression of HLA-DR (abundantly displayed on DC) with induced cytoplasmic CD83, a marker of early DC maturation used in that prior study, in monocytes procured from each of 3 CTCL patients, 3 GVHD patients and 3 normal subjects. The patient monocytes were obtained from the initial leukapheresis phase of ECP (pre ECP), and then processed through the actual online ECP exposure plate (ECP Day 0). The normal subject monocytes were obtained from an equivalent leukapheresis of normal subjects and were then processed through the laboratory equivalent of the ECP exposure plate.
As shown in Figure 1A , in all instances large increases in the percentage of processed monocytes, co-expressing HLA-DR and cytoplasmic CD83, were identified after 18 hr incubation of the treated cells (ECP Day 1). Overnight incubation produced 34% monocyte-to-DC conversion, an 8-fold increase in the expression of this standard DC marker over background levels.
This data revealed that the development of a DC phenotype is not limited to ECPtreated monocytes from CTCL patients, but also applies to those from GVHD patients and normal subjects. The absolute number of ECP-processed monocytes that expressed this DC phenotype after overnight incubation was assessed in cells from 6 patients and 3
normal subjects ( Figure 1B ). Electron microscopic examination confirmed the production of morphologically typical viable DC, able to bind, internalize and digest apoptotic lymphocytes.
Using co-expression of HLA-DR and CD83 positivity as the identity criterion, the one-day DC yield, from ECP processing of monocytes from normal subjects (54 -316 x 10 6 ), compares favorably to the total DC harvest from 6-day conventional GM-CSF/IL4 maturation of monocytes procured from full leukapheresis. Homogeneity of the ECP-induced DC population is indicated by the relatively uniform increase in CD86 (B7.2) expression ( Figure 3A ), compared to the more heterogeneous expression of co-stimulatory molecule on DC generated by 6 days incubation with GMCSF/IL4 ( Figure 3B ). Together, these results extend our previous studies in CTCL, 7 by demonstrating that monocytes from normal subjects, as well as those from patients, enter the DC differentiation pathway post ECP. T cell responses.
We next determined whether ECP-generated APC, procured after processing blood from three normal volunteers through the clinical ECP apparatus, were also capable of mediating cytotoxicity by targeting HLA on appropriate lymphoblasts. To ensure that the results directly reflect functional properties of those APC generated by ECP and intravenously returned to treated patients, we procured a unit of anti-coagulated blood from each normal volunteer and processed that blood through the actual ECP apparatus in a manner exactly equivalent to that of the clinical procedure. The experimental design sequentially involved ECP generation of APC from HLA-A2 Figure 5 , where it is noteworthy that ECP-APC more effectively stimulated cytotoxic T cell responses than did pretreatment APC from the same normal donor at similar stimulator-to-responder ratios.
Collectively, these findings reveal that ECP rapidly induces a large fraction of monocytes to assume phenotypic properties typical of DC. The ECP-generated APC are viable and capable of efficiently processing and presenting recall antigens to responsive CD4 T cells, as well as stimulating cytotoxic T cells against class I MHC targets.
ECP-induction of a distinctive transcriptome in processed monocytes
To determine whether ECP-induction of DC reflects organized direction of a high fraction of monocytes into the DC differentiation pathway, we studied differential gene expression in cells from 6 normal subjects, as well as from 3 ECP treated CTCL and 3 GVHD patients. ECP-induced alteration of gene expression was quantified as the fold change in RNA transcript levels from the pre-ECP baseline. In ECP, the processed 
Large ECP-induced changes in individual gene expressions
The stimulation by ECP of individual gene activation in monocytes was expressed as the ratio of ECP Day 1 to pre-ECP expression for the relevant gene. To preclude inadvertent gene induction during monocyte enrichment, a negative column purification method was used, whereby lymphocytes were retained and monocytes were passively filtered. The results revealed that the ECP-processed monocytes, from both patients and normal subjects, remain sufficiently viable to reproducibly express a shared transcriptome signature.
Genes were considered significantly up-or down-regulated by ECP, if fold change was (>2) and significance was (p<0.05), compared to pre ECP. Levels of RNA transcripts from approximately 3,000 genes were significantly changed in each patient group as well as in normal subjects (Table 1) . Overall, 1,129 genes were up-or downregulated in common by ECP-processed monocytes from both CTCL and GVHD patients as well as from normal subjects, indicating commonality in ECP-induced gene activation. only in normal subjects. However, display of both molecules was enhanced in all subjects by immunophenotyping (see Figure 2 for representative examples). This finding suggests that ECP stimulates transport of pre-formed co-stimulatory molecules to the DC surface, in addition to variable activation of the relevant genes.
For personal use only. on January 15, 2018. by guest www.bloodjournal.org From As would be expected during monocyte-to-DC maturation, CD14 (monocyte marker) expression was diminished, as assessed by measuring the mean fluorescence intensity on the monocyte populations of all patients and normal subjects, after overnight culture of ECP-processed monocytes. This result was confirmed in RT-PCR studies of the patients' post ECP cells (results not shown).
CD40, a co-stimulatory molecule expressed on mature DC, interacts with CD40 ligand on activated T cells and may enhance or prolong B7-1 & 2 T cell activation. 19 Decysin, a disintegrin/metalloprotease, is increased in LPS-matured DC and absent from monocytes and immature DC, 20 thereby serving as a marker of DC differentiation. CCR7
is a chemokine receptor required for DC migration to lymphoid organs, where the DC present antigen to naïve T cells. 21 Increased mRNA expression of CD83, a marker of maturing DC, [11] [12] [13] was identified only in normal subjects, while enhanced CD83 protein expression was detected by immunophenotyping in the cytoplasm of differentiating DC in all three groups ( Figure   2 The post-transcriptional
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Collectively, this transcriptional profiling reveals that cells from patients, as well as from normal subjects, activate or suppress multiple genes associated with differentiation of monocytes into maturing DC.
RT-PCR demonstration of ECP activation of DC-distinctive genes in monocytes
Because of the necessity of avoiding monocyte activation in the process of enriching the studied mononuclear populations, we used a negative affinity column enrichment method in which lymphocytes were retained by adherence to anti-T and B cell mAb conjugated to magnetic beads. The level of monocyte enrichment obtainable by this approach was limited to 60-80 percent, by factors and considerations intrinsic to our experimental design. ECP, through the impact of 8-MOP DNA crosslink's, initiates virtually universal apoptosis in the processed highly sensitive lymphocytes. 10 The resulting diminished surface expression of T and B cell differentiation antigens diminishes the affinity of these cells for affinity column, thereby limiting lymphocyte retention, leading to lymphocyte contamination of the passively transiting monocyte pool.
Although our preliminary findings had suggested that gene activation in the apoptotic contaminating lymphocytes does not discernibly contribute to the finding of prominent induction of DC distinctive genes, this possibility needed to be rigorously excluded.
For this purpose, we adapted the EasySep leukocyte enrichment method to enrich monocytes to >95% in the tested populations, also utilizing mAb-coated magnetic beads.
Since this approach did not involve column passage, we found that, despite the necessity of multiple purification cycles to remove the very large majority of the ECP-damaged lymphocytes, inadvertent activation of the battery of distinctive DC genes is avoided.
The availability of these more highly purified populations of ECP-processed monocytes then enabled us to confirm, by qRT-PCR, that the therapeutic procedure impressively stimulates expression of DC-distinctive genes. 
11-13
ECP was originally designed to enable the extracorporeal photoactivation of the DNA-crosslinking drug, 8-MOP, while blood is passaged as a 1mm film through the ECP plastic ultraviolet exposure plate. 2 We have previously shown that the passage through the plastic plate is critical for monocyte acquisition of the DC phenotype 7 , since leukapheresed monocytes incubated overnight only minimally differentiate to DC.
In the current study, we report that the large majority of the observed ECPinduced gene activation also requires passage through the plate and is first manifest after overnight incubation of the treated leukocytes. Now that the central importance of the exposure plate in ECP's induction of DC is recognized, we conclude that experimental animal systems which we and others have conceived and tested, 6, [33] [34] [35] lacking such an exposure plate, are not genuine ECP models.
Three factors appear to be required for the DC-induction: 1) adherence of plasma proteins to the plastic UVA exposure plate; 2) passage of monocytes through the plate; 
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Conflict of interest disclosure: CLB, RLE, RT, and MG are listed as co-inventors on Yale University-owned patents relating to monocyte-to-dendritic cell maturation. These patents have not been commercialized. Legend Table 3 : ECP-induced fold increase in expression of genes affecting monocyte adhesion, migration and signaling. Impact of treatment on gene expression is displayed as an Induced Expression Ratio (ratio of ECP Day 1 to pre-ECP expression for the relevant gene). RNA was isolated from 3 CTCL patients and 3 GVHD patients and 6 normal subjects at the relevant time points. Expression of each of eleven examined DC-distinctive genes was significantly enhanced by ECP processing, three and >1000 fold over that manifested by pretreatment monocytes. Nearly indistinguishable findings from identical analysis of non-purified mononuclear populations indicates that ECP-lethally damaged lymphocytes do not discernibly contribute to the observed expression of these genes, even when present in the study population.
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